Hepatic Small Vessel Neoplasm Mimics Prostate Cancer on 18F-DCFPyl PET/CT. (14th April 2023)

• Record Type: Journal Article
• Authors: Spinali, Keith L.; Papke, David J.; Shah, Hina J.
• Is Part Of: Clinical nuclear medicine. Volume 48:Number 4(2023)
• Page Start: e181
• Page End: e183
• Publication Date: 2023-04-14
• Subjects: 18F-DCFPyl -- hepatic small vessel neoplasm -- prostate-specific membrane antigen; Nuclear medicine -- Periodicals; Radioisotope scanning -- Periodicals; Nuclear Medicine -- Periodicals; 616.07575
• DOI: 10.1097/RLU.0000000000004554
• Languages: English
• ISSNs: 0363-9762

Abstract

Abstract: 18 F-DCFPyl is a Food and Drug Administration–approved radiotracer that targets prostate-specific membrane antigen and is used in the detection of recurrent or metastatic prostate cancer. As its use has increased, a growing number of nonprostatic disease entities have been identified that express prostate-specific membrane antigen and can mimic prostate cancer. Thus, the interpreting physician must also consider other variables such as serum prostate-specific antigen levels and the distribution of uptake to avoid an inappropriate diagnosis of metastatic prostate cancer. We describe 18 F-DCFPyl uptake associated with a hepatic small vessel neoplasm, an association previously undescribed in the literature.